Home LiteratureArticle Details
PMID: 25943106 Published · epublish English Journal Article Research Support, Non-U.S. Gov't

Carbon Ion irradiation in the treatment of grossly incomplete or unresectable malignant peripheral nerve sheaths tumors: acute toxicity and preliminary outcome.

Radiation oncology (London, England) ·Vol. 10 ·2015-05-06 ·页码 109

Jensen AD, Uhl M, Chaudhri N, Herfarth KK, Debus J, Roeder F

Abstract

To report our early experience with carbon ion irradiation in the treatment of gross residual or unresectable malignant peripheral nerve sheath tumors (MPNST). We retrospectively analysed 11 patients (pts) with MPNST, who have been treated with carbon ion irradiation (C12) at our institution between 2010 and 2013. All pts had measurable gross disease at the initiation of radiation treatment. Median age was 47 years (29-79). Tumors were mainly located in the pelvic/sacral (5 pts) and sinunasal/orbital region (5 pts). 5 pts presented already in recurrent situation, 3 pts had been previously irradiated, and in 3 pts MPNST were neurofibromatosis type 1 (NF1) associated. Median cumulative dose was 60 GyE. Treatment was carried out either as a combination of IMRT plus C12 boost (4 pts) or C12 only (7 pts). Median follow-up was 17 months (3-31 months). We observed 3 local progressions, translating into estimated 1- and 2-year local control rates of 65%. One patient developed distant failure, resulting in estimated 1- and 2-year PFS rates of 56%. Two patients have died, therefore the estimated 1- and 2-year OS rates are 75%. Acute radiation related toxicities were generally mild, no grade 3 side effects were observed. Severe late toxicity (grade 3) was scored in 2 patients (trismus, wound healing delays). Carbon ion irradiation yields very promising short term local control and overall survival rates with low morbidity in patients suffering from gross residual or unresectable malignant peripheral nerve sheath tumors and should be further investigated in a prospective trial.

MeSH 主题词
Adult Aged Female Heavy Ion Radiotherapy/adverse effects,mortality Humans Male Middle Aged Neoplasm Staging Neurilemmoma/mortality,pathology,radiotherapy Prognosis Radiation Injuries/etiology,mortality Radiotherapy Planning, Computer-Assisted/methods Retrospective Studies Survival Rate
作者与单位
共 6 位作者,点击展开单位 / ORCID
Jensen Alexandra D
Department of Radiation Oncology, University of Heidelberg, INF 400, 69120, Heidelberg, Germany. alexdjensen@gmx.de.
Uhl Matthias
Department of Radiation Oncology, University of Heidelberg, INF 400, 69120, Heidelberg, Germany. Matthias.Uhl@med.uni-heidelberg.de.
Chaudhri Naved
Department of Medical Physics, Heidelberg Ion Beam Therapy Centre (HIT), Heidelberg, Germany. Naved.Chaudhri@med.uni-heidelberg.de.
Herfarth Klaus K
Department of Radiation Oncology, University of Heidelberg, INF 400, 69120, Heidelberg, Germany. Klaus.Herfarth@med.uni-heidelberg.de.
Debus Juergen
Department of Radiation Oncology, University of Heidelberg, INF 400, 69120, Heidelberg, Germany. Juergen.Debus@med.uni-heidelberg.de. | Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Juergen.Debus@med.uni-heidelberg.de.
Roeder Falk
Department of Radiation Oncology, University of Heidelberg, INF 400, 69120, Heidelberg, Germany. Falk.Roeder@med.uni-muenchen.de. | Department of Molecular and Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. Falk.Roeder@med.uni-muenchen.de.
Article Info
Journal
Radiation oncology (London, England)
Abbr.
Radiat Oncol
ISSN
1748-717X
Published
2015-05-06
电子出版
2015-00-06
页码
109
Language
English
Country/Region
England
NLM ID
101265111
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com